Alopexx, Inc. has received investment from Biotech Consortia, Inc. to support the development and commercialization of its antimicrobial vaccine, AV0328.

ORIC Pharmaceuticals presented preclinical data on ORIC-944, a PRC2 inhibitor, showing potential as a best-in-class treatment for prostate cancer in combination with AR inhibitors.

Rocket Pharmaceuticals completed enrollment in the Phase 2 pivotal study of RP-A501 for Danon disease, with updated Phase 1 data expected at AHA 2024.

Douglas Tsao of H.C. Wainwright reaffirms a Buy rating for Xenon Pharmaceuticals, citing the promising efficacy and tolerability of its antiepileptic drug, azetukalner, supported by positive trial results and its impact on patients' emotional well-being.

Cycle Pharmaceuticals has launched VENXXIVA (tiopronin) Delayed-Release Tablets for treating cystinuria in the US, partnering with Torrent Pharma and Vanscoy Rare Pharmacy for distribution.

Appili Therapeutics formally terminated its arrangement agreement with Aditxt Inc. on May 30, 2025, following Aditxt's initial termination notice delivered on May 17, 2025.

Analyst Michael Yee from Jefferies maintains a Buy rating on Vertex Pharmaceuticals, citing strong future potential due to upcoming drug launches and underappreciated opportunities in its pipeline, including a new cystic fibrosis drug and a kidney pill in Phase 3 trials.

Rhythm Pharmaceuticals' HR chief, Pamela Cramer, sold $585,940 worth of stock under a pre-established trading plan, while also exercising stock options.

Longboard Pharmaceuticals initiated a Phase 3 clinical trial, DEEp SEA, to evaluate bexicaserin in Dravet syndrome patients aged 2-65 years.

Stoke Therapeutics is progressing zorevunersen (STK-001) for Dravet syndrome, with ongoing discussions with regulatory agencies for a global Phase 3 study.

MIRA Pharmaceuticals' Ketamir-2, a novel oral ketamine analog, outperformed gabapentin and pregabalin in preclinical neuropathic pain studies.

ANI Pharmaceuticals has received FDA approval for its Abbreviated New Drug Application (ANDA) for Estradiol Gel, 0.06%, a generic version of EstroGel.

Elutia Inc. reported the first commercial use of EluPro, an FDA-cleared antibiotic-eluting biologic envelope for pacemakers and neurostimulators, with full launch slated for 2025.

The FDA has approved Protega Pharmaceuticals' ROXYBOND™ (oxycodone hydrochloride) immediate-release 10 mg tablet, featuring SentryBond™ abuse-deterrent technology, for managing severe pain.

Shuttle Pharmaceuticals Holdings, Inc. has priced an underwritten public offering of 19,166,667 shares at $0.30 per share, expecting to raise approximately $5.75 million in gross proceeds.

Cybin Inc. has obtained FDA Breakthrough Therapy Designation for CYB003, a psychedelic-based therapy targeting Major Depressive Disorder.

Error occurred while parsing the model response.

The Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code (J9028) for ANKTIVA, effective January 1, 2025, to streamline billing.

Soleno Therapeutics reported a net loss of $76.6 million for the period ending September 30, 2024, a 605% increase compared to the same period in 2023.

Esperion Therapeutics reports a net product revenue increase of $10.8 million compared to Q3 2023, driven by prescription growth of NEXLETOL and NEXLIZET.